

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024

	Particulars		Quarter Ended		Half Year Ended		Year Ended	
		30th September, 2024	30th June 2024	30th Sep, 2023	30th September, 2024	30th Sep, 2023	31st March, 2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1.	Revenue							
	Revenue from Operations	4115.51	3010.47	2676.00	7125.98	4799.70	10639.63	
	Other Income	12.94	61.95	30.45	74.89	73.28	164.72	
п.	Total Income	4128.45	3072.42	2706.45	7200.87	4872.98	10804.35	
111.	Expenses							
(a)	Cost of Materials Consumed	1020.38	777.53	839.03	1797.91	1448.45	3214.31	
(b)	Purchase of Stock in trade	821.73	400.09	233.62	1221.83	593.81	1158.47	
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade,	(47.60)	(28.09)	48.04	(75.69)	(64.28)	(78.61)	
(d)	Employee benefits expense	820.42	803.50	620.94	1623.92	1187.50	2601.46	
(e)	Finance Costs	51.73	65.07	117.08	116.80	250.40	479.79	
(f)	Depreciation and amortisation expense	168.34	167.70	346.32	336.04	679.86	1228.71	
(g)	Other expenses	966.63	652.05	540.88	1618.68	984.95	2287.95	
	Total Expenses	3801.63	2837.85	2745.89	6639.49	5080.69	10892.08	
IV.	Profit / (Loss) before Exceptional Items and Taxes (II - III)	326.82	234.58	(39.44)	561.38	(207.71)	(87.73)	
ν.	Exceptional Items (Net)	0.00	0.00	4.52	0.00	4.52	5.51	
VI.	Profit / (Loss) before Tax	326.82	234.58	(43.95)	561.38	(212.22)	(93.24	
VII.	Tax Expenses							
	Current Tax	84.41	40.00	10.00	124.41	33.50	159.97	
14	Deferred Tax	(4.88)	19.61	(24.72)	14.73	(44.51)	(26.32	
VIII.	Net Profit / (Loss) after Tax	247.29	174.96	(29.23)	422.24	(201.22)	(226.89	
IX.	Other Comprehensive Income	0.00	0.00	0.00	0.00	(1.57)	6.17	
	(Net of Tax) - Net Credit / (Charge)						0.17	
х.	Total Comprehensive Income / (Loss)	247.29	174.96	(29.23)	422.24	(202.79)	(220.72	
	Paid up Equity Share Capital	3569.00	3569.00	3309.00	3569.00	3309.00	3309.00	
	(Face value ₹ 10/- each) Other Equity						6623.91	
XI.	Basic and diluted earnings per share	0.69	0.49	(0.10)	1.17	(0.63)	(0.72	

Notes:

1. The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 12th November 2024

2. During the Half year ended September, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant.

Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased.

3. The Company operates in one business segment i.e. "Pharmaceuticals".

4. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

5. The Statutory Auditors have expressed an unqualified opinion on the unaudited Standalone financials results for the quarter and half year ended 30th



Mumbai : 12th November, 2024.

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com



	Unaudited Statement of Ass	ets & Liabilitie	s as at 30th Septembe	r, 2024 (₹ in lakh	
Particulars			As at 30th September, 2024	As at 31st March, 2024	
	ASSETS				
1	Non-Current Assets				
	(a) Property, Plant and Equipment		4,728.41	4,579.93	
	(b) Capital Work- In- Progress		2,751.96	2,197.17	
	(c) Intangible assets		877.16	984.43	
	(d) Intangible assets under development		100.29	108.09	
			8,457.82	7,869.63	
	(e) Financial Assets				
	(i) Investments		3,240.30	3,240.30	
	(ii) Other Financial Assets		1,668.89	1,671.39	
	(f) Other Non Current Assets		630.32	746.06	
	(g) Non Current Tax Assets		72.00	74.63	
	(g) Non current lax Assets		5,611.51	5,732.38	
2	Current Assets		5,011.51	5,752.50	
-	(a) Inventories		967.96	055 02	
			967.96	955.83	
	(b) Financial Assets		1.00	4 74	
	(i) Investments		1.86	1.71	
	(ii) Trade Receivables		3,742.61	2,572.86	
	(iii) Cash and Cash Equivalents		102.87	588.58	
	(iv) Loans		159.21	223.92	
	(v) Other Financial Assets		491.74	282.78	
	(c) Other Current Assets		407.17	360.68	
			5,873.42	4,986.36	
_	Total Assets		19,942.75	18,588.37	
- 1	EQUITY AND LIABILITIES				
	Equity				
	(a) Equity Share capital		3,569.00	3,309.00	
	(b) Other Equity		9,506.40	6,623.90	
			13,075.40	9,932.90	
- 1	LIABILITIES				
1	Non-Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings		2,329.30	4,290.67	
	(ii) Lease Liabilities		125.84	125.84	
	(iii) Other Financial Liabilities		115.20	114.31	
	(b) Provisions		105.26	174.31	
	(c) Deferred Tax Liabilities (net)		387.29	372.56	
			3,062.89	5,077.69	
2	Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings		1,020.73	1,366.28	
	(ii) Lease Liabilities		40.10	82.22	
	(iii) Trade Payable				
	- Micro and Small Enterprise		141.64	82.56	
	- Other than Micro and Small Enterprise		1,420.56	1,008.10	
	(iv) Other Financial Liabilities	Tech	859.34	774.83	
	(b) Other Current Liabilities	(APOL)	165.63	114.44	
	(c) Provisions	17 13	156.47	149.34	
1000		(SMUMBAD)	3,804.47	3,577.78	
(-1)		Il and and			

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com



Lyka Labs Limited Unaudited Cash Flow Statement for the Half Year Ended 30th September, 2024

Particulars	For the Unit Verse	and ad 20th	For the Helf Vers F	adad 20th
rarticulars	For the Half Year ended 30th September, 2024		For the Half Year Ended 30t September, 2023	
	September,	2024	September, 2	023
A. Cash Flow from Operating Activities				
Profit / (Loss) for the Year before tax		561.38		(212.23)
Adjusted for				
Depreciation	336.04		679.86	
nterest Income	(17.32)		(31.82)	
inance Cost	116.80		250.40	
Provision for Employee Benefits	28.03		31.24	
Exchange rate fluctuation	(49.57)		(11.56)	
Exceptional Items	-		-	
Return on Investment	-		(0.03)	
		413.98		918.09
Operating profit before working capital change		975.36		705.87
Changes in Working Capital :				
Increase) / Decrease in Other Non-Current Financial Assets	2.50		(20.95)	
Increase) / Decrease in Other Non-Current Assets	115.74		(116.13)	
Increase) / Decrease in Inventories	(12.13)		(102.80)	
Increase) / Decrease in Trade and other receivables	(1,118.21)		(991.74)	
Increase) / Decrease in Other Current Financial Assets	(208.95)		79.86	
Increase) / Decrease in Other Current Assets	(46.49)		(71.72)	
Increase) / Decrease in Current Loans	64.71		323.29	
ncrease / (Decrease) in Other Non-Current Financial Liabilities	1.05		28.00	
ncrease / (Decrease) in Non-Current Provisions	(69.05)		(1.56)	
ncrease / (Decrease) in Trade Payables	471.54		264.18	
ncrease / (Decrease) in Other Current Financial Liabilities	88.95		(163.02)	
ncrease / (Decrease) in Other Current Liabilities	51.19		(41.47)	
ncrease / (Decrease) in Current Provisions	(22.87)		(17.99)	
hereise / (beerease) in earrent riovisions	(22.07)	(682.02)	(17.55)	(831.99)
Cash generated from operations		293.34	ł	(126.13)
Vet Income Tax Payment	(121.78)	(121.78)	(46.30)	(46.30)
Vet cashflow from operating activities (A)	(121.70)	171.56	(40.50)	(172.43)
B. Cashflow for Investing activities		1/1.50		(1/2.45)
Purchase of Fixed Assets	(924.24)		(309.76)	
Increase in Investment	(0.15)		(303.70)	
Sale of Fixed Assets	(0.13)			
Interest Received	17.32		31.82	
Net cash used in Investing activities (B)	17.52	(907.07)	51.02	(277.95)
C. Cashflow from Financing activities		(507.07)		(277.55)
Proceed from / (Repayment) of Non Current Borrowings Net	(1,975.36)		(1,882.64)	
Proceed from / (Repayment) of Current Borrowings Net	(373.85)		(160.51)	
Proceeds from Issue of Equity Shares and Warrants (Including Premium)	2,720.25		2,511.00	
Interest Paid				
Net cash used in Financing activities (C)	(121.24)	240.90	(476.08)	(0.22)
Net increase / (decrease) in cash and cash equivalents (A+B+C)		249.80	ŀ	(8.23)
		(485.71)	-	(458.61)
Cash and Cash Equivalents at the beginning of the Year Cash and Cash Equivalents	~	10.42		F 7 7 7 7
		19.43		57.77
Earmarked Balances		569.17	ŀ	811.79
Cash and Cash Equivalents at the and of the Very	2	588.60	-	869.58
Cash and Cash Equivalents at the end of the Year	3	17.00		40.75
Cash and Cash Equivalents Deposits with Banks (Rs 85.22 lakhs Lien against Bank Gurantee)	MBAI 3	17.66		42.75
HADDSTIS WITH BARKS INS 85 77 LAKING HAD BOBINGT BARK (STIFANTAA)		85.22		368.14
Deposits with banks (its 65.22 lakits cieff against bank durantee)		102.88	F	410.89



D. KOTHARY & CO. Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Lyka Labs Limited

- We have reviewed the accompanying Statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended September 30, 2024 and year to date from April 1, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
- 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Mumbai Date: 12th November, 2024



Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024

							Rs. In Lakhs
	Particulars	Quarter Ended		Half year Ended		Year Ended	
		30th September, 2024	30th June 2024	30th September, 2023	30th September, 2024	30th September, 2023	31st March, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Revenue						
	Revenue from Operations	4,115.51	3,011.40	2,798.65	7,126.91	5,086.35	11,119.46
	Other Income	2.66	55.88	24.62	58.54	62.18	145.47
П.	Total Income	4,118.17	3,067.28	2,823.27	7,185.45	5,148.53	11,264.93
III.	Expenses						
(a)	Cost of Materials Consumed	1,020.38	777.53	839.04	1,797.91	1,448.46	3,214.31
(b)	Purchase of Stock in trade	821.73	400.75	282.04	1,222.49	735.93	1,349.36
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade,	(47.60)	(28.09)	47.94	(75.69)	(64.40)	(78.50
(d)	Employee benefits expense	834.90	818.77	643.70	1,653.67	1,237.22	2,676.54
(e)	Finance Costs	54.30	64.71	118.77	119.01	253.91	489.09
(f)	Depreciation and amortisation expense	176.30	175.66	359.47	351.96	706.16	1,280.18
(g)	Other expenses	990.92	671.70	568.11	1,662.62	1,046.90	2,386.27
	Total Expenses	3,850.93	2,881.03	2,859.07	6,731.97	5,364.18	11,317.25
IV.	Profit / (Loss) before Exceptional Items and Taxes (II - III)	267.25	186.25	(35.80)	453.48	(215.65)	(52.32
v.	Exceptional Items (Net)		-	43.48	-	43.48	41.06
VI.	Profit / (Loss) before Tax	267.25	186.25	(79.28)	453.48	(259.13)	(93.37
VII.	Non Controlling Interest	(18.52)	(15.06)	(12.96)	(34.06)	(21.38)	(13.12
VIII	. Profit / (Loss) before Tax	285.77	201.31	(66.32)	487.54	(237.75)	(80.25
IV	Tax Expenses						
17.	Current Tax / Earlier Year Tax	84.41	40.00	13.93	124.41	48.24	186.93
	Deferred Tax	(8.29)	17.30	(31.60)		(52.67)	
		(6.25)	17.50	(51.00)	5.01	(52.07)	(10.20
х.	Net Profit / (Loss) after Tax	209.65	144.01	(48.65)	354.12	(233.32)	(248.92
	Other Comprehensive Income	2.09	(0.34)	2.14	1.75	0.57	10.54
XI.	(Net of Tax) - Net Credit / (Charge)	2.00	(0.0.1)		100		
XII.	. Total Comprehensive Income / (Loss)	211.74	143.67	(46.51)	355.87	(232.75)	(238.38
XIII	Paid up Equity Share Capital	3,569.00	3,569.00	3,309.00	3,569	3,309.00	3,309.00
	(Face value Rs.10/- each) Other Equity			-			3,506.43
	omer cyury						5,500.45
XIV	. Basic and diluted earnings per share	0.58	0.40	(0.16)	0.98	(0.73)	(0.79

Notes:


1. The above unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 12th November, 2024.

2. During the Half Year ended Sep, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant.

Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased. 3. The Company operates in one business segment i.e. "Pharmaceuticals".

4. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

5. The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the quarter and Half Year ended 30th Sepember, 2024.



inal Gandhi Managing Director & CEO DIN: 01516156

Mumbai; 12th November, 2024

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com



				(₹ in lakh
-	rticulars		As at 30th September, 2024	As at 31st March, 2024
	SETS			
	on-Current Assets			
(a)	1 1.		4,729.24	4,687.01
(b)	Capital Work- In- Progress		2,751.96	2,197.17
(c)			959.72	1,082.90
(d)	Intangible assets under development		100.29	108.09
			8,541.21	8,075.18
(e)				
	(i) Investments		9.22	7.47
	(ii) Other Financial Assets		1,673.03	1,675.53
(f)			630.32	746.06
(g)	Non Current Tax Assets		106.15	102.97
			2,418.72	2,532.03
2 Cu	rrent Assets			2427 T 1414
(a)			969.32	957.18
(b)	Financial Assets			
	(i) Investments		1.86	1.71
	(ii) Trade Receivables		3,778.33	2,699.25
	(iii) Cash and Cash Equivalents		111.06	594.88
	(iv) Loans		5.85	5.66
	(v) Other Financial Assets		550.58	341.18
(c)	Other Current Assets		448.03	465.36
			5,865.03	5,065.22
То	tal Assets		16,824.95	15,672.42
EC	UITY AND LIABILITIES			
Eq	uity			
(a)	Equity Share Capital		3,569.00	3,309.00
1. State 1.	Other Equity		6,322.08	3,506.43
Eq	uity attributable to owners of the company		9,891.08	6,815.43
(c)			(22.47)	11.1:
	n and a set of the set		9,868.61	6,826.54
LI	ABILITIES			
1 No	on-Current Liabilities	1		
(a)				
1	(i) Borrowings		2,329.30	4,290.6
	(ii) Lease Liabilities		40.10	125.84
	(ii) Other Financial Liabilities		115.20	100.30
(b) Provisions		114.31	182.23
(c)	- A CONTRACT OF	м м.	391.77	382.76
1			2,990.68	5,081.8
2 0	rrent Liabilities		2,000100	
) Financial Liabilities			
1,0	(i) Borrowings		1,020.73	1,366.28
	(ii) Lease Liabilities		125.84	82.22
	(iii) Trade Payables due to :		125.04	02.2
	- Micro and Small Enterprise		165.83	103.23
			1,439.38	1,107.0
	- Other than Micro and Small Enterprise	BSL		
1	(iv) Other Financial Liabilities	15 3	877.02	828.13
1.00) Other Current Liabilities	- ANDAN SAN FI	175.92	125.4
(c)) Provisions	Stan Im	160.94	151.6
		12-0	3,965.66	3,764.03

Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002. • Phone : 02646 221422 / 220549 • Fax : 02640-250692 CIN L24230GJ1976PLC008738

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com



Lyka Labs Limited

Unadited Consolidated Cash Flow Statement for the Half Year Ended 30th September, 2024

Particulars	For the Half ye	or the Half year Ended 30th		ar Ended 30th
	Septem	per, 2024	Septemb	er, 2023
A. Cash Flow from Operating Activities				
Profit / (Loss) for the year before tax		453.47		(259.13
Adjusted for				
Depreciation	351.96		706.16	
Interest Income	(9.93)		(70.79)	
Finance Cost	119.01		253.91	
Provision for Doubtful Trade Receivables, Advances, Employee Benefits	37.89		52.66	
Exchange rate fluctuation	(49.58)		(18.13)	
Exceptional Items	-		-	
Return on Investment	(0.15)	449.20	(0.84)	022.07
Operating profit before working capital change		902.67		922.97 663.84
Changes in Working Capital :				
(Increase) / Decrease in Other Non-Current Financial Assets	2.50		(20.95)	
(Increase) / Decrease in Other Non-Current Assets	115.74		(116.13)	
(Increase) / Decrease in Inventories	(12.14)		(102.92)	
(Increase) / Decrease in Trade and other receivables	(1,033.87)		(928.84)	
(Increase) / Decrease in Other Current Financial Assets	(209.40)		142.20	
(Increase) / Decrease in Other Current Assets	17.33		(147.49)	
(Increase) / Decrease in Non-Current Loans			-	
(Increase) / Decrease in Current Loans	(0.19)		(341.20)	
Increase / (Decrease) in Other Non-Current Financial Liabilities	15.00		28.00	
Increase / (Decrease) in Non-Current Provisions	(67.91)		(0.53)	
Increase / (Decrease) in Trade Payables	394.93		277.26	
Increase / (Decrease) in Other Current Financial Liabilities	53.33		(164.27)	
Increase / (Decrease) in Other Current Liabilities	50.45		(42.75)	
	A CONTRACT OF A		2 C C C C C C C C C C C C C C C C C C C	
Increase / (Decrease) in Current Provisions	(24.21)		(19.05)	(1 436 67)
Cash generated from operations		(698.44) 204.23		(1,436.67) (772.84)
Net Income Tax Payment	(127.59)	(127.59)	(59.92)	(772.84) (59.92)
Net income fax Payment Net cashflow from operating activities (A)	(127.59)	76.64	(59.92)	(832.75)
		70.04		(052.75)
B. Cashflow for Investing activities	(919.00)		(200 77)	
Purchase of Fixed Assets	(818.00)		(309.77)	
Sale of Fixed Assets	-		-	
Interest Received	9.93	(000.07)	70.79	(220.00)
Net cash used in Investing activities (B)		(808.07)		(238.98)
C. Cashflow from Financing activities	(2.000.00)		(1.00.1.0.0)	
Proceed from / (Repayment) of Non Current Borrowings Net	(2,252.30)		(1,924.64)	
Proceed from / (Repayment) of Current Borrowings Net	(96.90)		207.94	
Proceeds from Issue of Equity Shares and warrants (Including Premium)	2,720.25		2,511.00	
Interest Paid	(123.45)		(479.59)	
Net cash used in Financing activities (C)		247.60		314.71
Net increase / (decrease) in cash and cash equivalents (A+B+C)		(483.83)		(757.02)
Cash and Cash Equivalents at the beginning of the year				560000 ana
	Si	25.71		274.19
Earmarked Balances	12M	569.17		896.89
Cash and Cash Equivalents at the end of the year	IBAI E	594.88		1,171.08
cash and cash Equivalents at the end of the year	In	25.04		40.04
Cash and Cash Equivalents	-01	25.84		48.94
Deposits with Banks (Rs 85.22 lakhs Lien against Bank Guarantee)	/	85.22		368.24
		111.06		417.18



D. KOTHARY & CO. Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year-to-Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Lyka Labs Limited

- We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Lyka Labs Limited ("the Parent"), which includes its subsidiaries (the Parent and its Subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2024 and year-to-date from April 1, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

i) Lyka Labs Limited

Subsidiaries

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited
- 5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/ information reflects total assets of Rs. 720.14 lakhs as at September 30, 2024, total revenues of Rs. 10.50 lakhs and Rs. 20.02 lakhs, total net profit/ (loss) after tax of Rs. (56.17) lakhs and Rs. (102.17) lakhs and total comprehensive income of Rs. (54.09) lakhs and Rs. (100.43) lakhs, for the quarter ended September 30, 2024 and year-to-date from April 1, 2024 to September 30, 2024 respectively, and net cash inflow of Rs. 1.90 lakhs as at September 30, 2024, which have been reviewed by us.







6. Based on our review conducted and procedures performed as stated in para 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co. Chartered Accountants Firm Registration No. 105335W

THAR Deepak O. Narsaria MUMBAI (Partner) Membership No. 121190 PEDACCO

UDIN: 24/2/190BKBOX J283

Place: Mumbai Date: 12th November, 2024